This excerpt taken from the GENZ 8-K filed Feb 14, 2007.
Genzymes non-GAAP gross margin is expected to be approximately 77-78 percent of revenue this year, consistent with the gross margin for 2006.
This excerpt taken from the GENZ 8-K filed Feb 17, 2005.
Total gross margin is expected to be in the range of 77-78 percent of revenue, compared with 74 percent in 2004. Several factors account for this increase: improved product margins for Synvisc, improved margins for Renagel resulting from the transition to in-house manufacturing, and improved margins for lysosomal storage disorder products resulting from increased utilization of manufacturing facilities.